UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)

☒	QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2021

☐	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

COMMISSION FILE NUMBER 001-39555

GREENWICH LIFESCIENCES, INC.

(Exact Name of registrant as specified in its charter)

Delaware		20-5473709
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

3992 Bluebonnet Dr., Building 14, Stafford, Texas		77477
(Address of principal executive offices)		(Zip Code)

(832) 819-3232

(Registrant’s telephone number, including area code)

Title of each class:		Trading Symbol(s)		Name of each exchange on which registered:
Common Stock		GLSI		Nasdaq Capital Market

Indicate by check mark whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated
filer ☐

Accelerated filer ☐

Non-accelerated filer ☒

Smaller reporting
company ☒

Emerging growth
company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of November 1, 2021, the issuer had 13,123,377 shares of Common Stock issued and outstanding.

GREENWICH LIFESCIENCES, INC.

Table of Contents

		Page

PART I	FINANCIAL INFORMATION	3

Item 1.	Financial Statements (unaudited)	3

	Balance Sheets as of September 30, 2021 (Unaudited) and December 31, 2020	3

	Statements of Operations for the Three and Nine Months Ended September 30, 2021 and 2020 (Unaudited)	4

	Statements of Stockholders’ Equity (Deficit) for the Three and Nine Months Ended September 30, 2021 and 2020 (Unaudited)	5

	Statements of Cash Flows for the Nine Months Ended September 30, 2021 and 2020 (Unaudited)	6

	Notes to Financial Statements (Unaudited)	7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	9

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	11

Item 4.	Controls and Procedures	12

PART II	OTHER INFORMATION	12

Item 1.	Legal Proceedings	12

Item 1A.	Risk Factors	12

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	12

Item 3.	Defaults Upon Senior Securities	12

Item 4.	Mine Safety Disclosures	12

Item 5.	Other Information	12

Item 6:	Exhibits	13

SIGNATURES		14

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

GREENWICH LIFESCIENCES, INC.

BALANCE SHEETS

AS OF SEPTEMBER 30, 2021 (UNAUDITED AND DECEMBER 31, 2020

	September 30, 2021			December 31, 2020
Assets
Current assets
Cash	$	28,905,993		$	28,660,375
Total current assets		28,905,993			28,660,375
Acquired patents, net		13,518			16,227
Total assets	$	28,919,511		$	28,676,602

Liabilities and stockholders’ deficit
Current liabilities
Accounts payable & accrued interest	$	295,845		$	710,971
Unreimbursed expenses		159,274			59,367
Advance from related party/shareholder		—			275,154
Total current liabilities		455,119			1,045,492
Total liabilities		455,119			1,045,492

Stockholders’ equity

Common stock, $0.001 par value; 100,000,000 shares authorized; 12,993,609 and 12,703,541 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively		12,994			12,704

Additional paid-in capital		59,738,222			56,695,359
Accumulated deficit		(31,286,824	)		(29,076,953	)
Total stockholders’ equity		28,464,392			27,631,110
Total liabilities and stockholders’ equity	$	28,919,511		$	28,676,602

See accompanied notes to unaudited financial statements.

GREENWICH LIFESCIENCES, INC.

STATEMENTS OF OPERATIONS

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2021 AND 2020 (UNAUDITED)


	Three Months Ended September 30,						Nine Months Ended September 30,
	2021			2020			2021			2020
Revenue	$	—		$	—		$	—		$	—
Operating expenses
Research and development		657,096			158,031			1,495,607			458,726
General and administrative		209,590			98,834			725,130			253,210
Total operating expenses		866,686			256,865			2,220,737			711,936
Loss from operations		(866,686	)		(256,865	)		(2,220,737	)		(711,936	)
Interest Income		3,568			—			10,866			—
Net loss	$	(863,118	)	$	(256,865	)	$	(2,209,871	)	$	(711,936	)
Per share information:
Net loss per common share, basic and diluted	$	(0.07	)	$	(0.03	)	$	(0.17	)	$	(0.08	)
Weighted average common shares outstanding, basic and diluted		12,968,891			8,788,032			12,826,249			8,628,958

See accompanied notes to unaudited financial statements.

GREENWICH LIFESCIENCES, INC.

STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER, 2021 AND 2020 (UNAUDITED)


	Common Stock				Preferred Stock						Additional						Total Stockholders’
	Shares		Par Amount		Shares			Par Amount			Paid-in Capital			Accumulated Deficit			Equity (Deficit)
Balances, December 31, 2019		8,458,048	$	8,458		1,980,365		$	1,981		$	25,853,134		$	(27,213,991	)	$	(1,350,418	)
Stock-based compensation		77,571		78		—			—			173,865			—			173,943
Issuance of common stock in initial public offering, net of offering costs
Issuance of common stock in initial public offering, net of offering costs, shares
Additional preferred stock issued due to anti-dilution		-		-		-			-			-			-			-
Additional preferred stock issued due to anti-dilution, shares		-		-		-			-			-			-			-
Conversion of preferred to common stock
Conversion of preferred to common stock, shares
Exercise of common stock from Green Shoe of follow-on offering, net of offering costs
Exercise of common stock from Green Shoe of follow-on offering, net of offering costs, shares
Net loss															(244,641	)		(244,641	)
Balances, March 31, 2020		8,535,619		8,536		1,980,365			1,981			26,026,999			(27,458,632	)		(1,421,116	)
Stock-based compensation		77,571		78		—			—			173,865			—			173,943
Net loss															(210,430	)		(210,430	)
Balances, June 30, 2020		8,613,190		8,614		1,980,365			1,981			26,200,864			(27,669,062	)		(1,457,603	)
Stock-based compensation		73,356		73		—			—			164,978			—			165,051
Issuance of common stock in initial public offering, net of offering costs		1,260,870		1,260		—			—			6,206,242			—			6,207,502
Additional preferred stock issued due to anti-dilution		—		—		42,404			42			(42	)		—			—
Conversion of preferred to common stock		2,022,769		2,023		(2,022,769	)		(2,023	)		—			—			—
Net loss															(256,865	)		(256,865	)
Balances, September 30, 2020		11,970,185	$	11,970		—		$	—		$	32,572,042		$	(27,925,927	)	$	4,658,085

Balances, December 31, 2020		12,703,541	$	12,704		—		$	—		$	56,695,359		$	(29,076,953	)	$	27,631,110
Stock-based compensation		73,356		73		—			—			164,978			—			165,051
Exercise of common stock from Green Shoe of follow-on offering, net of offering costs		70,000		70		—			—			2,547,930			—			2,548,000
Net loss															(597,008	)		(597,008	)
Balances, March 31, 2021		12,846,897		12,847		—			—			59,408,267			(29,673,961	)		29,747,153
Balances		12,846,897		12,847		—			—			59,408,267			(29,673,961	)		29,747,153
Stock-based compensation		73,356		73		—			—			164,978			—			165,051
Net loss															(749,745	)		(749,745	)
Balances, June 30, 2021		12,920,253		12,920		—			—			59,573,245			(30,423,706	)		29,162,459
Beginning balances, value		12,920,253		12,920		—			—			59,573,245			(30,423,706	)		29,162,459
Stock-based compensation		73,356		74		—			—			164,977			—			165,051
Net loss															(863,118	)		(863,118	)
Balances, September 30, 2021		12,993,609	$	12,994		—		$	—		$	59,738,222		$	(31,286,824	)	$	28,464,392
Balances		12,993,609	$	12,994		—		$	—		$	59,738,222		$	(31,286,824	)	$	28,464,392

See accompanied notes to unaudited financial statements.

GREENWICH LIFESCIENCES, INC.

STATEMENTS OF CASH FLOWS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2021 AND 2020 (UNAUDITED)


	Nine Months Ended September 30,
	2021			2020
Operating activities:
Net loss	$	(2,209,871	)	$	(711,936	)
Adjustments required to reconcile net loss to net cash used in operating activities:
Amortization		2,709			2,706
Stock-based compensation		495,153			512,937
Changes in operating assets and liabilities:
Accounts payable		(451,732	)		15,000
Accrued interest		36,606			54,910
Unreimbursed expenses (accrued)		99,907			126,383
Net cash used in operating activities		(2,027,228	)		—
Financing activities:
Proceeds from sale of common stock		2,548,000			—
Repayment to related party/shareholder		(275,154	)		—
Net proceeds from initial public offering of common stock		—			6,207,502
Net cash provided by (used in) financing activities		2,272,846			6,207,502
Net increase (decrease) in cash		245,618			6,207,502
Cash, beginning of period		28,660,375			6,835
Cash, end of period	$	28,905,993		$	6,214,337

Non-cash investing and financing activities:
Conversion of preferred stock to common					2,023
Issuance of preferred stock due to antidilution					42

See accompanied notes to unaudited financial statements.

GREENWICH LIFESCIENCES, INC.
NOTES TO FINANCIAL STATEMENTS
(UNAUDITED)

1. Organization and Description of the Business

Greenwich LifeSciences, Inc. (the “Company”) was incorporated in the state of Delaware in 2006 under the name Norwell, Inc. In March 2018, Norwell, Inc. changed its name to Greenwich LifeSciences, Inc. The Company is developing a breast cancer immunotherapy focused on preventing the recurrence of breast cancer following surgery.

2. Significant Accounting Policies

Basis of Presentation

The accompanying unaudited interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission and should be read in conjunction with the audited financial statements and notes thereto of the Company contained elsewhere herein.

In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim periods presented have been reflected herein. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements that would substantially duplicate the disclosures contained in the audited financial statements of the Company for the years ended December 31, 2020 and 2019 as reported in the Company’s Form 10-K have been omitted.

Basic and Diluted Loss per Share

As of September 30, 2021 and 2020, the Company has common stock equivalents related to underwriter warrants outstanding to acquire 100,870 shares of the Company’s common stock.

As of September 30, 2021 and 2020, the Company has no common stock equivalents related to convertible preferred stock issued and outstanding.

The following table sets forth the computation of basic and diluted net loss per common share for the periods indicated:


	Nine Months Ended September 30,
	2021			2020
Basic and diluted net loss per share calculation:
Net loss, basic		(2,209,871	)		(711,936	)
Change in fair value of warrants		—			—
Net loss, diluted		(2,209,871	)		(711,936	)
Weighted average common shares outstanding, basic and diluted		12,826,249			8,628,958
Net loss per common share, basic and diluted	$	(0.17	)	$	(0.08	)

3. Related Party Transactions

Unreimbursed expenses have been accrued and incurred by management, which total $159,274 as of September 30, 2021 and $59,367 as of December 31, 2020. Between January 1, 2021 and March 15, 2021, the Company paid off the remaining related party loans of $155,154 and $120,000 to Snehal Patel and the Kenneth Hallock and Annette Hallock Revocable Trust, respectively.

4. Commitments and Contingencies

License Obligation, Legal Expenses, and Manufacturing Agreements

The Company entered into an exclusive license agreement with The Henry M. Jackson Foundation (“HJF”) in April 2009, as amended, pursuant to which it acquired exclusive marketing rights to GP2, the Company’s product candidate. In consideration for such licensed rights, the Company issued HJF 202,619 shares of the Company’s common stock valued at $0.267 per share, which is amortized over 15 years at $3,607 per year. Pursuant to the exclusive license agreement, the Company is required to pay an annual maintenance fee, milestone payments and royalty payments based on sales of GP2 and to reimburse HJF for patent expenses related to GP2. The Company currently depends on third-party contract manufacturers for all required raw materials, active pharmaceutical ingredients, and finished product candidate for the Company’s clinical trials.

The Company paid HJF an aggregate total of $434,732 in July 2021 related to annual maintenance fees and reimbursement of patent expenses. Accounts payable includes accrued patent and license obligations to HJF, including accrued interest, plus accrued expenses for manufacturing of GP2 for the upcoming Phase III clinical trial, which total $295,845 as of September 30, 2021 and $710,971 as of December 31, 2020.

Legal Proceedings

From time to time, the Company may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of business. Any of these claims could subject the Company to costly legal expenses and, while management generally believes that there will be adequate insurance to cover different liabilities at such time the Company becomes a public company and commences clinical trials, the Company’s future insurance carriers may deny coverage or policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on the results of operations and financial position. Additionally, any such claims, whether or not successful, could damage the Company’s reputation and business. The Company is currently not a party to any legal proceedings, the adverse outcome of which, in management’s opinion, individually or in the aggregate, could have a material adverse effect on our results of operations or financial position.

5. Stockholders’ Equity

As of September 30, 2021, 599,493 shares of the 908,242 shares of the common stock grant had vested at approximately $1,348,859 value and 308,749 shares remain unvested and unrecognized at approximately $694,685 value. An aggregate of 220,068 shares of common stock were vested at approximately $495,153 value in January through September 2021 in consideration for services rendered.

On January 29, 2021, in connection with our December 2020 follow-on offering, the underwriter exercised its option to purchase 70,000 additional shares of common stock at the public offering price of $40.00 per share for gross proceeds of $2,800,000 and net proceeds of $2,548,000, after deducting underwriting discounts and commissions and offering expenses borne by the Company, which totaled $252,000.

Warrants

At September 30, 2021, outstanding underwriter warrants to purchase shares of common stock accounted for as equity or liabilities were as follows with an aggregate intrinsic value as of September 30, 2021 of $3,940,991 based on the September 30, 2021 closing share price of $39.07:

Schedule of Outstanding Warrants

Shares Underlying
Outstanding		Exercise		Expiration
Warrants		Price⁽¹⁾		Date⁽¹⁾
	100,870	$	7.1875	September 24, 2025
	100,870

(1)

The underwriter warrants are exercisable at any time and from time to time, in whole or in part, during a period commencing March 24, 2021 and expiring September 24, 2025. The exercise price of the warrants is $7.1875 per share or $6.9718 per share if the warrants are exercised for cash within the first six months of the period in which they are exercisable.

6. Subsequent Events

On October 19, 2021, the underwriter warrants were partially exercised resulting in the issuance of 80,696 shares of common stock and gross proceeds to the Company of $562,596. As of October 19, 2021, warrants to purchase 20,174 shares of common stock remain outstanding.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward-Looking Statements

This Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements other than statements of historical facts contained in this Quarterly Report, including statements regarding the future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions.

In addition, our business and financial performance may be affected by the factors that are discussed under “Risk Factors” in the Annual Report on Form 10-K for the year ended December 31, 2020, filed on March 31, 2021. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time and it is not possible for us to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

You should not rely upon forward-looking statements as predictions of future events. We cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

The following discussion and analysis is qualified in its entirety by, and should be read in conjunction with, the more detailed information set forth in the financial statements and the notes thereto appearing elsewhere in this Quarterly Report on Form 10-Q. This discussion should not be construed to imply that the results discussed herein will necessarily continue into the future, or that any conclusion reached herein will necessarily be indicative of actual operating results in the future. Such discussion represents only the best present assessment of our management.

Overview

We are a biopharmaceutical company that is developing GP2, an immunotherapy designed to prevent the recurrence of breast cancer following surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. In a completed Phase IIb clinical trial led by MD Anderson Cancer Center, no recurrences were observed in the HER2/neu 3+ adjuvant setting after median 5 years of follow-up, if the patient received the 6 primary intradermal injections over the first 6 months. We are planning to commence a Phase III clinical trial shortly and are currently completing the last steps to release GP2 drug product and to open clinical sites.

To date, we have not generated any revenue and we have incurred net losses. Our net losses were approximately $1.9 million and $3.4 million for the years ended December 31, 2020 and 2019, respectively and $2.2 million and $0.7 million for the nine months ended September 30, 2021 and 2020.

Our net losses have resulted from costs incurred in developing the drug in our pipeline, planning and preparing for clinical trials and general and administrative activities associated with our operations. We expect to continue to incur significant expenses and corresponding increased operating losses for the foreseeable future as we continue to develop our pipeline. Our costs may further increase as we conduct clinical trials and seek regulatory approval for and prepare to commercialize our product candidate. We expect to incur significant expenses to continue to build the infrastructure necessary to support our expanded operations, clinical trials, commercialization, including manufacturing, marketing, sales and distribution functions. We will also experience increased costs associated with operating as a public company.

Results of Operations for the Three Months Ended September 30, 2021 and 2020

Research and Development Expenses

Research and development expenses increased by $499,065, or 316%, to $657,096 for the three months ended September 30, 2021 from $158,031 for the three months ended September 30, 2020. The increase was primarily the result of an increase in compensation and manufacturing and clinical expenses.

General and Administrative Expenses

General and administrative expenses increased by $110,756, or 112%, to $209,590 for the three months ended September 30, 2021 from $98,834 for the three months ended September 30, 2020. The increase was primarily the result of an increase in costs for raising capital.

Results of Operations for the Nine Months Ended September 30, 2021 and 2020

Research and Development Expenses

Research and development expenses increased by $1,036,881, or 226%, to $1,495,607 for the nine months ended September 30, 2021 from $458,726 for the nine months ended September 30, 2020. The increase was primarily the result of an increase in compensation and manufacturing and clinical expenses.

General and Administrative Expenses

General and administrative expenses increased by $471,920, or 186%, to $725,130 for the nine months ended September 30, 2021 from $253,210 for the nine months ended September 30, 2020. The increase was primarily the result of an increase in costs for raising capital.

Liquidity and Capital Resources

Since our inception in 2006, we have devoted most of our cash resources to research and development and general and administrative activities. We have not yet achieved commercialization of our product and have a cumulative net loss from our operations. We will continue to incur net losses for the foreseeable future. Our financial statements have been prepared assuming that we will continue as a going concern.

We will require additional capital to meet our long-term operating requirements. We expect to raise additional capital through the sale of equity and/or debt securities; however, there is no assurance that we will be successful at raising additional capital in the future. If our plans are not achieved and/or if significant unanticipated events occur, we may have to further modify our business plan, which may require us to raise additional capital. As of September 30, 2021 and December 31, 2020, our principal source of liquidity was our cash, which totaled $28,905,993 and $28,660,375, respectively, and additional loans and accrued unreimbursed expenses from related parties. Historically, our principal sources of cash have included proceeds from the sale of common stock and preferred stock and related party loans. Our principal uses of cash have included cash used in operations. We expect that the principal uses of cash in the future will be for continuing operations, funding of research and development, including our clinical trials, and general working capital requirements.

Cash Flow Activities for the Nine Months Ended September 30, 2021 and 2020

We incurred net losses of $2,209,871 and $711,936 during the nine month periods ended September 30, 2021 and 2020, respectively. The increase was primarily the result of an increase in compensation, manufacturing and clinical trial expenses, and costs for raising capital.

Operating Activities

Net cash used in operating activities was $2,027,228 for the nine months ended September 30, 2021 and $0 for the nine months ended September 30, 2020.

Investing Activities

We did not use or generate cash from investing activities during the nine months ended September 30, 2021 and September 30, 2020.

Financing Activities

We used and generated cash netting a total of $2,272,846 from financing activities during the nine months ended September 30, 2021 and $6,207,502 from financing activities during the nine months ended September 30, 2020.

Off-Balance Sheet Arrangements

As of September 30, 2021, we did not have any off-balance sheet arrangements as described by Item 303(a)(4) of Regulation S-K.

Critical Accounting Policies

Stock-Based Compensation

Compensation expense related to warrants and stock granted to employees and non-employees is measured at the grant date based on the estimated fair value of the award and is recognized on a straight-line basis over the requisite service period. Forfeitures are recognized as a reduction of stock-based compensation expense as they occur. Stock-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized and any previously recognized compensation expense is reversed.

Recent Accounting Pronouncements

We have evaluated the following recent accounting pronouncements through the date the financial statements were issued and filed with the SEC and believe that none of them will have a material effect on our financial statements:

In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, “Leases: Topic 842” (“ASU 2016-02”), to supersede nearly all existing lease guidance under GAAP. The guidance would require lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets. ASU 2016-02 is effective for the Company in the first quarter of its fiscal year ending December 31, 2019 using a modified retrospective approach with the option to elect certain practical expedients. The Company has no material leases, thus the adoption of ASU 2016-02 will have no material impact on the Company’s financial statements.

In May 2016, the FASB issued ASU 2016-12, Revenue from Contracts from Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients. The amendments in this update affect the guidance in ASU 2014-09. The core principle of the guidance in Topic 606 is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The amendments in ASU 2016-12 do not change the core principle of the guidance in Topic 606, but instead affect only the narrow aspects noted in Topic 606. Topic 606 became effective for the Company on December 1, 2018. The Company has no revenue, thus the adoption of ASU 2016-12 will have no material impact on the Company’s financial statements.

In June 2018, the FASB issued ASU 2018-07, “Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting,” which modifies the accounting for share-based payment awards issued to nonemployees to largely align it with the accounting for share-based payment awards issued to employees. ASU 2018-07 is effective for us for annual periods beginning January 1, 2019. The Company evaluated ASU 2018-07 and determined that the adoption of this new accounting standard did not have a material impact on the Company’s financial statements.

JOBS Act

On April 5, 2012, the JOBS Act was enacted. Section 107 of the JOBS Act provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended (“Securities Act”) for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.

We have chosen to take advantage of the extended transition periods available to emerging growth companies under the JOBS Act for complying with new or revised accounting standards until those standards would otherwise apply to private companies provided under the JOBS Act. As a result, our financial statements may not be comparable to those of companies that comply with public company effective dates for complying with new or revised accounting standards.

Subject to certain conditions set forth in the JOBS Act, as an “emerging growth company,” we intend to rely on certain of these exemptions, including, without limitation, (i) providing an auditor’s attestation report on our system of internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act and (ii) complying with any requirement that may be adopted by the Public Company Accounting Oversight Board (“PCAOB”) regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements, known as the auditor discussion and analysis. We will remain an “emerging growth company” until the earliest of (i) the last day of the fiscal year in which we have total annual gross revenues of $1.07 billion or more; (ii) the last day of our fiscal year following the fifth anniversary of the date of the completion of our initial public offering; (iii) the date on which we have issued more than $1 billion in nonconvertible debt during the previous three years; or (iv) the date on which we are deemed to be a large accelerated filer under the rules of the SEC.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We maintain “disclosure controls and procedures,” as defined in Rule 13a-15(e) and Rule 15d-15(e) under the Exchange Act that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.

Our management, with the participation of our principal executive officer and principal accounting and financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act), as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on such evaluation, our principal executive officer and principal accounting and financial officer has concluded that as of September 30, 2021, our disclosure controls and procedures were not effective as of such date as a result of material weaknesses in our internal control over financial reporting due to inadequate segregation of duties within account processes due to limited personnel and insufficient written policies and procedures for accounting, IT and financial reporting and record keeping. Under the direction of our principal executive officer and principal financial and accounting officer, we are developing a plan to remediate the material weaknesses.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting during our most recent fiscal quarter that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Limitations on Effectiveness of Controls and Procedures

Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives as specified above. Management does not expect, however, that our disclosure controls and procedures will prevent or detect all errors and fraud. Any control system, no matter how well designed and operated, is based upon certain assumptions and can provide only reasonable, not absolute, assurance that its objectives will be met. Further, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the Company have been detected.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

From time to time, we may be subject to litigation and claims arising in the ordinary course of business. We are not currently a party to any material legal proceedings and we are not aware of any pending or threatened legal proceeding against us that we believe could have a material adverse effect on our business, operating results, cash flows or financial condition.

ITEM 1A. RISK FACTORS

There have been no material changes from the risk factors disclosed in our Form 10-K for the year ended December 31, 2020.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

Exhibit Number		Description of Exhibit

31.1		Certification of Chief Executive Officer and Principal Financial and Accounting Officer required by Rule 13a-14(a)/15d-14(a) under the Exchange Act.

32.1		Certification of Chief Executive Officer and Principal Financial and Accounting Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS		Inline XBRL Instance Document

101.SCH		Inline XBRL Taxonomy Extension Schema

101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase

101.LAB		Inline XBRL Taxonomy Extension Labels Linkbase

101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase

101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase

104		Cover Page Interactive Data File - the cover page from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 is formatted in Inline XBRL

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	GREENWICH LIFESCIENCES, INC.

November 15, 2021	By:	/s/ Snehal Patel
		Snehal Patel
		Chief Executive Officer (Principal Executive Officer and Principal Accounting and Financial Officer)

SEC Form 10-Q filed by Greenwich LifeSciences, Inc.